KT-413, a Novel IRAKIMiD Degrader of IRAK4 and IMiD Substrates, has a Differentiated MOA that Leads to Single-agent and Combination Regressions in MYD88MT Lymphoma Models
June 20, 2021
16th Annual International Conference on Malignant Lymphoma (ICML) Virtual Meeting
Area of Focus
Oncology
Programs
Other
Indications
Other
Development Stage
Pre-clinical Data
Share
